The American Diabetes Association (ADA) recommends that T2DM patients who have elevated plasma alanine aminotransferase (ALT) or steatosis of liver should be screened and evaluated for liver fibrosis and NASH, and that screening for NAFLD should focus on identifying patients with liver fibrosis, among whom early intervention may prevent progression to the decompensated cirrhotic stage [13]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.